Literature DB >> 17464240

Cancer as a manifestation of aberrant chromatin structure.

Malcolm V Brock1, James G Herman, Stephen B Baylin.   

Abstract

In this article we review many important epigenetic changes in early carcinogenesis and discuss the possibility of these alterations being targeted for therapeutic intervention in the future. Both regional DNA methylation and global chromatin packaging are interrelated partners that function in concert to control gene transcription. We first summarize briefly DNA methylation and its role in gene expression. Then, we focus on how the DNA is packaged into chromatin and the tight relationship between chromatin and DNA methylation. A more complete understanding of these key, regulatory events is vital in approaching a more rational drug therapy to various malignancies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17464240      PMCID： PMC3586529          DOI： 10.1097/PPO.0b013e31803c5415

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  62 in total

Review 1.  Methylation-induced repression--belts, braces, and chromatin.

Authors:  A P Bird; A P Wolffe
Journal:  Cell       Date:  1999-11-24       Impact factor: 41.582

Review 2.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 3.  The cancer epigenome--components and functional correlates.

Authors:  Angela H Ting; Kelly M McGarvey; Stephen B Baylin
Journal:  Genes Dev       Date:  2006-12-01       Impact factor: 11.361

4.  Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a.

Authors:  Viktor Janzen; Randolf Forkert; Heather E Fleming; Yoriko Saito; Michael T Waring; David M Dombkowski; Tao Cheng; Ronald A DePinho; Norman E Sharpless; David T Scadden
Journal:  Nature       Date:  2006-09-06       Impact factor: 49.962

Review 5.  Polycomb silencers control cell fate, development and cancer.

Authors:  Anke Sparmann; Maarten van Lohuizen
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

6.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors:  Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

7.  Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells.

Authors:  Paul A Reynolds; Mahvash Sigaroudinia; Giuseppe Zardo; Matthew B Wilson; Geoffrey M Benton; Caroline J Miller; Chibo Hong; Jane Fridlyand; Joseph F Costello; Thea D Tlsty
Journal:  J Biol Chem       Date:  2006-06-09       Impact factor: 5.157

8.  p16INK4a induces an age-dependent decline in islet regenerative potential.

Authors:  Janakiraman Krishnamurthy; Matthew R Ramsey; Keith L Ligon; Chad Torrice; Angela Koh; Susan Bonner-Weir; Norman E Sharpless
Journal:  Nature       Date:  2006-09-06       Impact factor: 49.962

9.  Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing.

Authors:  Anna V Molofsky; Shalom G Slutsky; Nancy M Joseph; Shenghui He; Ricardo Pardal; Janakiraman Krishnamurthy; Norman E Sharpless; Sean J Morrison
Journal:  Nature       Date:  2006-09-06       Impact factor: 49.962

10.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.

Authors:  Hiromu Suzuki; D Neil Watkins; Kam-Wing Jair; Kornel E Schuebel; Sanford D Markowitz; Wei Dong Chen; Theresa P Pretlow; Bin Yang; Yoshimitsu Akiyama; Manon Van Engeland; Minoru Toyota; Takashi Tokino; Yuji Hinoda; Kohzoh Imai; James G Herman; Stephen B Baylin
Journal:  Nat Genet       Date:  2004-03-14       Impact factor: 38.330
View more
  21 in total

Review 1.  DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology.

Authors:  Jian Tajbakhsh
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

2.  Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control.

Authors:  Seema Somji; Scott H Garrett; Xu Dong Zhou; Yun Zheng; Donald A Sens; Mary Ann Sens
Journal:  Toxicol Environ Chem       Date:  2010-10       Impact factor: 1.437

3.  p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex.

Authors:  Merlin Nithya Gnanapragasam; J Neel Scarsdale; Maria L Amaya; Heather D Webb; Megha A Desai; Ninad M Walavalkar; Shou Zhen Wang; Sheng Zu Zhu; Gordon D Ginder; David C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-13       Impact factor: 11.205

4.  Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Li-Ru He; Meng-Zhong Liu; Bin-Kui Li; Hui-Lan Rao; Yi-Ji Liao; Xin-Yuan Guan; Yi-Xin Zeng; Dan Xie
Journal:  BMC Cancer       Date:  2009-12-22       Impact factor: 4.430

Review 5.  Epigenetics in NG2 glia cells.

Authors:  Sarah Moyon; Jialiang Liang; Patrizia Casaccia
Journal:  Brain Res       Date:  2015-06-17       Impact factor: 3.252

6.  R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters.

Authors:  Paul A Ginno; Paul L Lott; Holly C Christensen; Ian Korf; Frédéric Chédin
Journal:  Mol Cell       Date:  2012-03-01       Impact factor: 17.970

7.  E2F1 coregulates cell cycle genes and chromatin components during the transition of oligodendrocyte progenitors from proliferation to differentiation.

Authors:  Laura Magri; Victoria A Swiss; Beata Jablonska; Liang Lei; Xiomara Pedre; Martin Walsh; Weijia Zhang; Vittorio Gallo; Peter Canoll; Patrizia Casaccia
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

Review 8.  Fourier phase based depth-resolved nanoscale nuclear architecture mapping for cancer detection.

Authors:  Shikhar Uttam; Yang Liu
Journal:  Methods       Date:  2017-11-07       Impact factor: 3.608

9.  Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

Authors:  Li-Ning Xu; Xin Wang; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

10.  Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.

Authors:  Adriana S Beltran; Xueguang Sun; Paul M Lizardi; Pilar Blancafort
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.